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ABSTRACT
Objective: This work was delineated to assess procalcitonin (PCT) and C-reactive protein (CRP) as prognostic markers for cardiovascular complication 
in type 2 diabetic patients.
Methods: Forty diabetic patients without cardiovascular disease (CVD), 40 diabetic patients with CVD, and 20 healthy control counterparts were 
participated in this study. Serum PCT and CRP levels were assayed and correlated with metabolic parameters. Receiver operating characteristic (ROC) 
curve analysis was done for each biochemical marker.
Results: The mean level of PCT was 707.17±99.19 ng/l in diabetic patients versus 881.30±123.56 ng/l for the cardio-diabetic patients (p<0.0001). 
The mean value of CRP was 34.43±17.27 mg/l in diabetic patients versus 50.32±20.19 mg/l for the cardio-diabetic patients (p=0.0003). PCT levels 
were significantly amplified in the cardio-diabetic patients with increasing CRP, triglycerides (TG), fasting blood glucose (FBG), and cholesterol 
(p=0.004, 0.0005, 0.002, and 0.01, respectively). CRP levels were significantly enhanced in the cardio-diabetic patients with increasing TG, FBG, 
cholesterol, and microalbumin (p=0.002, 0.047, 0.003, and 0.001 respectively).  ROC curve analysis for PCT and CRP revealed that the area under 
curve (AUC) was 0.878 and 0.727, respectively. These findings indicate the good validity of the above biomarkers especially PCT as a prognostic 
marker for cardiovascular complication in type 2 diabetic patients.
Conclusion: This study evidences the usefulness of measuring serum levels of PCT and CRP in diagnosis of cardiovascular complication in type 2 
diabetic patients.
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INTRODUCTION
Diabetes mellitus is a chronic disease that affects 415 million people 
worldwide, and 5 million people died from diabetic complications [1]. 
Type 2 diabetes mellitus (T2DM) is manifested by hyperglycemia that 
results from lack of insulin or resistance to the action of insulin in the 
muscle, fat, and liver in addition to an inadequate response by the 
pancreatic beta cells [2].
Uncontrolled diabetes for the first few years can cause acute cardiac 
and renal complications which are life-threatening, whereas 
poorly controlled diabetes can cause long-term cardiac and renal 
complications [3]. This is due to a complex group of risk factors 
associated with T2DM including insulin resistance, hyperglycemia, 
diabetic dyslipidemia, hypertension, hyperinsulinemia, systemic 
inflammation, and adipose tissue-derived factors [4-6]. Worth 
mentioning, the changes in the mass and metabolism of adipose tissue 
may be paralleled by insulin resistance and visceral obesity commonly 
associated with T2DM [7].
Inflammatory mediators play a critical role in the development of 
cardiovascular disease (CVD). In particular, acute coronary syndrome 
(ACS) is an inflammatory disease and the serum levels of inflammatory 
factors, such as interleukin (IL)-6, IL-18 and C-reactive protein (CRP), 
are used to detect patients with CVD, especially coronary artery disease 
(CAD) [8]. Moreover, CRP has been found to be significantly elevated in 
patients with acute myocardial infarction [9].
CRP is a well-known acute inflammatory marker that has been used as 
a mediator of infection [10]. These two factors are easy in assessment, 
reliable, and inexpensive, and they are used for the diagnosis and 
follow-up of several diseases [10,11]. Procalcitonin (PCT) is produced 
during bacterial infections, sepsis, cardiogenic shock, major surgery, 
burns, multiple trauma, and after cardiac surgery [12,13]. It is a 
hormone of 116 amino acids and it is implicated in calcium metabolism. 
First, it is recognized as prohormone of calcitonin, which is synthesized 
by the medullary C-cells of the thyroid gland [14-16]. Nonetheless, 
even thyroidectomized patients showed PCT response during acute 
inflammation [17] indicating that there are other probable origins of 
PCT production.
Some investigators have suggested that PCT may be produced by the 
liver and inflammatory cells [18,19]. The inflammatory response is an 
essential feature of ACS and myocardial infarction (MI). In acute MI (AMI), 
signs of inflammation are well identified and the amplified levels of acute 
phase reactants have been found to be linked to a worse short- and 
long-term prognosis [20]. Signs of the systemic inflammatory response, 
such as fever, leukocytosis, and the enhanced acute-phase reactants, are 
frequently shown in patients with ACS [21]. PCT has been manifested as 
a novel cardiac marker in AMI [22]. Circumstantial evidence showed that 
bacterial endotoxins and tumor necrosis factor-α (TNF-α) both induced 
PCT in vitro [13,23]. Based on this document, PCT may be considered as 
an alternative new valuable prognostic marker in ACS. Many research 
studies have cited higher PCT levels in patients versus healthy controls 
following severe sepsis, cardiac surgery, or trauma [24-26].
The focus of our interest was to detect the kinetics of procalcitonin 
production, compared with CRP, as a novel prognostic marker for 
cardiovascular complications in type 2 diabetic patients.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i9.19524
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METHODS
Forty diabetic patients with CVD (cardio-diabetic group) and forty 
diabetic patients without evidence of CVD (diabetic group) were included 
in the current study. In addition, twenty healthy participants who with 
no history of T2DM, other endocrine dysfunctions, hyperlipidemia, 
hypertension, or coronary heart diseases (CHDs) were enrolled in 
the study and served as controls. Clinical evidence of CVD included 
MI or coronary artery bypass surgery, stroke, and peripheral arterial 
disease. Patients in the group without vascular disease were T2DM 
patients who had no history of vascular disease and those with normal 
electrocardiogram findings at exercise and normal peripheral artery 
Doppler ultrasonography. Exclusion criteria involved the presence of 
sustained Type 1 DM, acute and chronic infections, malignancy, hepatic 
or renal disease, diabetic retinopathy and nephropathy, and other 
endocrine dysfunctions. This study was approved by Ethical Committee 
of Ethics Commission and Scientific Research of the General Authority 
for Hospitals and Educational Institutes.
Venous blood and urine samples were collected from all participants 
and each blood sample was divided into two portions. The small 
portion was collected on EDTA-coated tube and the large portion was 
collected on EDTA-free coated tube. Serum samples were obtained by 
centrifugation and the biochemical variables were measured on the 
same day of the blood collection. Remaining serum specimens were 
stored at −20°C until analysis of PCT and CRP levels.
Quantitative determination of serum glucose was carried out 
colorimetrically using commercial kits purchased from Randox 
Laboratories (Crumlin, County Antrim, United Kingdom) using 
method of Thomas [27]. Quantitative estimation of serum cholesterol 
was done colorimetrically using commercial kits purchased from 
Randox Laboratories using method of Richmond [28]. Serum high 
density lipoprotein (HDL)-cholesterol was assayed colorimetrically 
using commercial kits purchased from Randox Laboratories using 
method of Assmann [29]. Low density lipoprotein (LDL)-cholesterol 
was quantified in serum using a kit provided by Spinreact (Girona, 
Spain) for the quantitative determination of serum LDL-cholesterol 
following the method of Okada et al. [30]. Triglycerides (TG) in serum 
were measured colorimetrically using commercial kit purchased 
from Randox Laboratories according the method of Jacobs and 
Van Denmark [31]. Glycated hemoglobin was determined using 
a kit provided by Spinreact for the quantitative determination of 
glycated hemoglobin according to the method described by Trivelli 
et al. [32]. Serum CRP was measured by ELISA using commercial 
kit purchased from Immunospec Corporation (Canoga Park, USA) 
following the method of Hedlund [33]. Quantitative estimation of 
microalbumin in urine was done by immunoturbidimetric assay 
using commercial kit purchased from Pointe Scientific, INC (Canton, 
USA) according to the method of Mogensen and Schmitz [34]. Serum 
PCT was evaluated by solid phase enzyme-linked immunosorbent 
assay (ELISA kit) using 96-well microplates supplied by Glory 
Science Co., Ltd (Del Rio, USA) in accordance with the method 
described by Arkader et al. [35].
Statistical analysis
Data were expressed as mean±standard deviation and analyzed using 
MedCalc software, version 11. The Student’s t-test was used to assess 
the significance of difference in the levels of PCT and CRP between the 
patient groups (diabetic and cardio-diabetic) and the control group. 
The correlation analysis between serum PCT and CRP level and other 
measured parameters in the different studied groups was done by 
correlation coefficient test. The cut-off value was determined for each 
of the studied parameters in the current study according to the best 
discrimination between diabetic patients and cardio-diabetic patients 
regarding optimal values of sensitivity and specificity using receiver 
operating characteristic (ROC) curves analysis. Area under the curve 
(AUC) of the ROC curve was calculated for each test. p<0.05 was 
accepted as significant.
RESULTS
Laboratory assessments of the measured parameters in the different 
submitted groups are presented in Table 1. Cholesterol, CRP, FBG, 
hemoglobin A1c (HbA1c), LDL, TG, microalbumin, and PCT levels were 
significantly higher in diabetic patients than in healthy individuals 
(p=0.022, p<0.0001, p<0.0001, p<0.0001, p=0.042, p=0.007, p=0.016, 
and p<0.0001, respectively). Likewise, CRP, FBG, HbA1c, LDL, TG, 
cholesterol, PCT, and microalbumin levels were significantly higher 
in cardio-diabetic patients than in healthy individuals (p<0.0001, 
p<0.0001, p<0.0001, p<0.0001, p=0.009, p=0.007, p<0.0001, and 
p<0.0001, respectively). In addition, CRP, LDL, PCT, and microalbumin 
levels were significantly higher in cardio-diabetic patients as compared 
to diabetic patients (p=0.0003, p<0.0001, p<0.0001, and p<0.0001, 
respectively). Whereas, HDL level showed significant drop in cardio-
diabetic patients versus diabetic patients and controls (p=0.0002 and 
p<0.0001, respectively). Furthermore, it revealed significant decline in 
diabetic patients relative to healthy participants (p=0.038) (Table 1).
The results of correlation between serum PCT concentration and 
metabolic parameters in the different studied groups are depicted 
in Table 2. Significant positive correlation between serum PCT 
Table 1: Laboratory assessments in the different studied groups
Parameters Control subject (C) Diabetic patients (D) Cardio-diabetic patients (CD) P1 P2 P3
Cholesterol (mg/dl) 194.15±36.70 225.70±54.40 233.02±57.47 0.022 0.007 0.56
140.00-252.00 135.00-383.00 69.00-378.00
CRP (mg/l) 14.53±6.92 34.43±17.27 50.32±20.19 <0.0001 <0.0001 0.0003
4.80-25.10 16.10-75.30 19.20-89.80
FBG (mg/dl) 87.40±6.91 256.07±101.2 272.80±103.09 <0.0001 <0.0001 0.466
75.00-101.00 105.00-589.00 127.00-606.00
HbA1c (%) 5.45±0.51 9.74±1.67 10.16±2.10 <0.0001 0.0001 0.325
4.30-6.30 6.60-14.70 6.80-15.90
HDL (mg/dl) 40.25±7.67 35.35±8.8 27.57±8.83 0.038 <0.0001 0.0002
28.00-55.00 10.00-47.00 15.00-45.00
LDL (mg/dl) 122.90±25.04 146.25±46.94 202.47±36.48 0.042 <0.0001 <0.0001
77.00-159.00 64.00-278.00 118.00-298.00
TG (mg/dl) 121.60±55.44 183.47±91.76 237.70±187.56
75.00-307.00 35.00-417.00 71.00-981.00 0.007 0.009 0.104
Procalcitonin (ng/l) 381.67±140.2 707.17±99.19 881.30±123.56 <0.0001 <0.0001 <0.0001
200.50-642.20 505.0-880.0 610.0-1150.0
Microalbumin (mg/ml) 7.48±3.29 11.61±7.07 37.78±13.97 0.016 <0.0001 <0.0001
0.60-12.0 0.30-31.10 8.28-68.90
P1: Diabetic group compared to control group. P2: Cardio-diabetic group compared to control group. P3: Cardio-diabetic group compared to diabetic group. 
CRP: C-reactive protein, FBG: Fasting blood glucose, HbA1c: Hemoglobin A1c, HDL: High-density lipoprotein, LDL: Low-density lipoprotein, TG: Triglycerides
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concentration and cholesterol, TG, CRP, and FBG has been determined 
in cardio-diabetic patients (p=0.011, p=0.0005, p=0.004, and p=0.002, 
respectively). As well, significant positive correlation between serum 
PCT concentration and LDL, cholesterol, TG, CRP, FBG, and HbA1C 
has been recorded in diabetic patients (p=0.052, p=0.013, p=0.003, 
p<0.0001, p<0.0001, and p=0.009, respectively). However, significant 
negative correlation has been observed between serum PCT and 
microalbumin in diabetic patients (p=0.016) (Figs. 1 and 2).
The data of correlation between serum CRP level and other measured 
biochemical markers in the different studied groups are illustrated 
in Table 3. Significant positive correlation between serum CRP level 
and cholesterol, TG, FBG, PCT, and microalbumin in cardio-diabetic 
patients has been demonstrated (p=0.003, p=0.002, p=0.047, p=0.004, 
and p=0.001, respectively). Similarly, significant positive correlation 
between serum CRP level and LDL, cholesterol, TG, FBG, HbA1c, and 
PCT has been detected in diabetic patients (p=0.004, p=0.001, p=0.004, 
p=0.0001, p=0.047, and p<0.0001, respectively). Meanwhile, significant 
negative correlation has been recorded between serum CRP level and 
HDL and microalbumin in diabetic patients (p=0.047 and p=0.018, 
respectively) (Figs. 3 and 4).
The receiving operating characteristic (ROC) curve is designed for 
PCT and CRP (Figs. 5 and 6). The cut-off values for PCT and CRP were 
750 ng/l, and 42.1 mg/l, respectively. AUC for PCT and CRP was 0.878 
and 0.727, respectively. This result indicated the good validity of the 
above biochemical markers particularly PCT to discriminate diabetic 
patients from cardio-diabetic patients.
DISCUSSION
Type 2 diabetic patients have a high risk for CVD. This risk is 
accompanied by many factors such as hypertension, dyslipidemia, and 
obesity in these patients. However, the onest of CVD in type 2 diabetic 
patients is not linked with the high prevalence of traditional risk 
factors only, but other non-traditional risk factors may be implicated. 
Thus, CVD is increased in type 2 diabetic patients due to a complex 
combination of various traditional and non-traditional risk factors. This 
has a critical role to play in the evolution of atherosclerosis over its long 
natural history from endothelial function to clinical events [36]. The 
objective of this study was to assess PCT and CRP as prognostic markers 
for cardiovascular complications in patients with T2DM.
The results obtained in this study showed that cholesterol, LDL, and TG are 
significantly increased in diabetic patients relative to controls whereas, 
HDL is significantly decreased in diabetic patients versus the controls. 
These results are in conformity with those of Ali and Al Hadidi [37] who 
stated that all the above parameters are significantly higher in T2DM 
group, whereas HDL is significantly lower in T2DM group in respect 
with the control group. These results are explained by Ronald [38] 
who cited that insulin resistance may contribute in the development of 
dyslipidemia in diabetic patients. As in type 2 diabetes, insulin resistance 
increases the flow of free fatty acids from adipose tissue and impairs 
insulin-mediated skeletal muscle uptake of free fatty acids resulting in 
increased fatty acid flow to the liver [39,40]. The increased free fatty 
acid levels in individuals with impaired glucose tolerance suggesting 
that insulin resistance is related to the elevated free fatty acid levels 
which occur before the onset of hyperglycemia [41]. Many investigators 
have demonstrated a relationship between plasma free fatty acid 
levels and insulin resistance [42]. Free fatty acids in the form of TG are 
deposited in the muscle, liver, heart, and pancreas in the presence of 
insulin resistance. Furthermore, insulin resistance increases the activity 
of hepatic lipase, which is responsible for hydrolysis of phospholipids 
into LDL and HDL particles with consequent formation of very small 
and dense LDL particles and a reduction in HDL particles [43,44]. This 
hypothesis is appreciated when some drugs that lowered the high level 
of free fatty acids (thiazolidinediones) could improve insulin sensitivity 
in the muscle, liver, and adipose tissues [45,46].
FBG and HbA1c levels are significantly enhanced in diabetic patients 
comparing with healthy individuals. These results are in harmony with 
Table 2: Correlation between serum procalcitonin concentration and metabolic parameters in the different studied groups
Parameters Serum procalcitonin level 
in control groups
Serum procalcitonin level 
in diabetic group
Serum procalcitonin level 
in cardio-diabetic groups
r p r p r p
Cholesterol (mg/dl) 0.231 0.325 0.385 0.013* 0.395 0.011*
TG (mg/dl) 0.688 0.0008** 0.448 0.003** 0.524 0.0005**
HDL (mg/dl) 0.245 0.296 −0.281 0.078 0.207 0.198
LDL (mg/dl) 0.132 0.576 0.308 0.052* 0.185 0.250
CRP (mg/l) −0.133 0.575 0.760 <0.0001** 0.437 0.004**
FBG (mg/dl) −0.416 0.068 0.718 <0.0001** 0.470 0.002**
HbA1c (%) 0.337 0.146 0.4036 0.009** 0.211 0.190
Microalbumin (mg/ml) 0.230 0.327 −0.377 0.016* 0.292 0.067
r=Correlation coefficient, *p<0.05, **p<0.01, not significant (p>0.05). CRP: C-reactive protein, FBG: Fasting blood glucose, HbA1c: Hemoglobin A1c, HDL: High-density 
lipoprotein, LDL: Low-density lipoprotein, TG: Triglycerides
Table 3: Correlation between serum CRP level and and metabolic parameters in the different studied groups
Parameters Serum CRP level in 
control groups
Serum CRP level in 
diabetic group
Serum CRP level in 
cardio-diabetic groups
r p r p r p
Cholesterol (mg/dl) 0.490 0.028* 0.476 0.001** 0.446 0.003*
TG (mg/dl) 0.327 0.158 0.442 0.004* 0.471 0.002*
HDL (mg/dl) 0.278 0.234 −0.315 0.047* −0.119 0.463
LDL (mg/dl) 0.265 0.257 0.444 0.004* 0.240 0.135
FBG (mg/dl) −0.049 0.844 0.588 0.0001** 0.315 0.047*
HbA1c (%) −0.265 0.258 0.315 0.047* 0.095 0.558
Microalbumin (mg/ml) 0.530 0.016* −0.370 0.018* 0.491 0.001**
Procalcitonin (ng/l) −0.133 0.575 0.760 <0.0001** 0.437 0.004**
r=Correlation coefficient, *p<0.05, **p<0.01, not significant (p>0.05). CRP: C-reactive protein, FBG: Fasting blood glucose, HbA1c: Hemoglobin A1c, HDL: High-density 
lipoprotein, LDL: Low-density lipoprotein, TG: Triglycerides
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the study of Ali and Al Hadidi [37] who revealed that FBG and HbA1C levels 
are significantly higher in diabetic patients than in healthy individuals. 
Furthermore, Makris et al. [47] recorded a significant relation between 
FBG and HbA1C in diabetic patients. The studies of Peterson et al. [48] 
and Miedema [49] have shown that the increased blood glucose leads 
to the increased attachment of glucose molecules to the hemoglobin 
in red blood cells. The long period of hyperglycemia in the blood, the 
more glucose binds to hemoglobin in the red blood cells and the higher 
in glycated hemoglobin. It is formed in a non-enzymatic glycationgly 
pathway of hemoglobin exposure to plasma glucose; then, reaction 
occurs between glucose and the N-end of the beta chain in hemoglobin. 
In diabetes mellitus, higher amounts of glycated hemoglobin indicating 
a poorer control of blood glucose levels with consequent complications 
such as CVD, nephropathy, neuropathy, and retinopathy.
CRP level is significantly elevated in diabetic patients relative to healthy 
individuals. These results are in keeping with those of Belfki et al. [50] 
who demonstrated that levels of CRP are significantly elevated in 
patients with T2DM versus controls. Morohoshi et al. [51] and Guha 
et al. [52] mentioned that hyperglycemia stimulates the liberation of the 
inflammatory cytokine such as IL-6 and TNF-α from different cell types 
and results in the secretion of acute phase reactants by adipocytes. 
Grunfeld et al. [53] and Hirschfield et al. [54] proved that CRP is an 
acute phase reactant that is produced primarily in the liver under the 
activation of adipocyte-derived proinflammatory cytokines.
Serum PCT level is significantly amplified in diabetic patients relative to 
controls. Our results are in harmony with those of Soylemez et al. [55] 
who reported that PCT levels are elevated in type 2 diabetic patients 
compared with healthy controls. In addition, Schiopu et al. [56] found 
that PCT is positively correlated with the presence of hyperglycemia and 
with systolic blood pressure. Moreover, hyperglycemia is accompanied 
by increased systemic inflammatory activation and thus, it seems that 
this inflammation may stimulate PCT production.
These investigators explained the elevated levels of PCT in type 2 
diabetic patients by the fact that T2DM is related to oxidative stress 
and advanced glycation end-products (AGEs) elevation. AGEs interact 
with its receptor called RAGE. Potentiation of RAGE leads to regulation 
of the transcription factor, nuclear factor-kB, and its target genes and 
also of activator protein-1(AP-1). These factors could ultimately lead to 
upregulation of PCT gene expression.
Fig. 1: Correlation between different metabolic parameters and serum procalcitonin concentration in diabetic group
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There are significantly higher differences in microalbumin between 
diabetic patients and controls. These findings echo those of pervious study 
of Chowta et al. [57] who found high prevalence of microalbuminuria 
(37%) in T2DM, and the incidence of microalbuminuria increases with 
the increased duration of diabetes mellitus. Mogensen et al. [58] proved 
a positive correlation between microalbuminuria and the duration of 
diabetes mellitus. Long duration of diabetes has significant contribution 
for the development of microalbuminuria. Prolonged exposure to 
hyperglycemia causes AGEs accumulation. Bucala et al. [59] and Tan 
et al. [60] stated that hyperglycemia may cause tissue damage by several 
mechanisms, one of which is non-enzymatic glycation of intra- and 
extra-cellular proteins. Glucose has a reactive aldehyde moiety which 
reacts non-enzymatically with the amino groups of proteins in the 
extracellular matrix, producing reversible Amadori products, and AGEs 
that can impair degradation of proteins, and induce cytotoxic pathways. 
Hence, serum levels of AGEs increased in type 2 diabetic patients, and 
this leads to increased level of microalbumin.
Cholesterol, TG, and LDL are significantly increased in cardio-diabetic 
group relative to healthy control group. Meanwhile, HDL is significantly 
decreased in cardio-diabetic patients versus healthy individuals. This 
finding is in respect with the study of Haddad et al. [61] who found 
that cholesterol, LDL-C, and TG levels are increased but HDL-C level is 
decreased in diabetic patients with CAD compared with those in control 
group. These data are explained by Celermajer [62] who mentioned 
that dyslipidemia is a critical mechanism by which atherosclerosis 
and endothelial dysfunction can occur in diabetic patients. Healthy 
endothelium regulates activation of platelet, tone of the blood vessel, 
leukocyte adhesion, inflammation, and thrombogenesis. Thus, 
healthy endothelium is antiatherogenic, vasodilatory, and anti-
inflammatory [62]. Affection of these mechanisms results in the 
generation of atherosclerosis. Therefore, both insulin resistance and 
insulin deficiency lead to dyslipidemia accompanied by increased 
glycosylation, oxidation, and TG enrichment of lipoproteins.
Fig. 2: Correlation between different metabolic parameters and serum procalcitonin concentration in cardio-diabetic group
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Furthermore, Dokken [63] has shown that oxidized LDL is 
proatherogenic because when the particles of LDL are oxidized, they 
showed new properties that are recognized by the immune system as 
“foreign.” Furthermore, oxidized LDL induces many abnormal biological 
responses, such as promoting the capability of leukocytes to ingest 
lipids and differentiate into foam cells, attracting leukocytes to the 
intima of the vessel, and stimulating leukocytes, endothelial cells (ECs), 
and smooth muscle cell (SMC) proliferation [64]. All of these results 
in the generation of atherosclerotic plaque. Furthermore, in diabetic 
patients, LDL particles can glycated, in a process similar to the glycation 
of hemo globin. Glycation of LDL prolongs its half-life [65] and therefore 
increased the capability of LDL to induce atherogenesis.
FBG and HbA1C levels are significantly elevated in cardio-diabetic 
patients relative to the controls. These results are in harmony 
with those of Anping et al. [66] who stated that levels of HbA1C are 
gradually increased in unstable angina (UA) and AMI patients versus 
healthy individuals. Biologically, glycated hemoglobin is an advanced 
glycosylation end-product, and the increased level of HbA1C causes the 
formation of advanced glycosylation end-product, which attaches to 
the vessel wall and leads to dysfunction of endothelium and oxidative 
stress progression [67,68]. Furthermore, the binding of advanced 
glycosylation end-product is associated with overproduction of 
inflammatory mediators like CRP [69]. Increased CRP level has been 
shown to be significantly linked with the instability of plaque [70,71]. 
This explains why that after adjustifying CRP, there is no significant 
association between HbA1c and the severity of CAD. Finally, increased 
level of advanced glycosylation end-product interferes with the 
endogenous fibrinolytic system which may lead to high risk of coronary 
artery stenosis [72].
CRP is significantly elevated in cardio-diabetic patients in respect to 
healthy individuals. Our results come in line with those of Ridker [73] 
who proved that the increased level of CRP is related to an 8-fold increase 
Fig. 3: Correlation between different metabolic parameters and serum C-reactive protein level in diabetic group
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in cardiovascular mortality. Furthermore, Liang et al. [74] stated that 
the level of CRP is significantly enhanced in AMI and UA patients than 
in stable angina patients and healthy control. These observations are 
interpreted by Shrivastava et al. [75] who reported that atherosclerotic 
process is characterized by low-grade inflammation and increased level 
of the inflammatory modulators. In addition, CRP is also generated 
locally the in atherosclerotic lesions by inflamed SMCs lymphocytes 
and monocytic cells.
Paffen and DeMaat [76] and Pfützner et al. [77] found that CRP plays 
a critical role in many aspects of atherogenesis including activation of 
the classical pathway of the complement system. Through this action, 
CRP directly facilitates the innate immunity, a process that has already 
been related to the development and progression of CHD [77]. CRP 
increases LDL uptake into macrophages and enhances the capability of 
macrophages to form foam cells. Moreover, CRP upregulates adhesion 
molecules expression in ECs that can attract monocytes to the site of 
injury. Therefore, CRP is a high sensitive biomarker that can be used for 
diagnosis, management, and prognosis of CHD [78].
Serum PCT level is significantly enhanced in cardio-diabetic patients 
versus healthy controls. Similar results have been obtained by Sinning 
et al. [78] who cited that patients with ACS have increased concentration 
of PCT. Likewise, Sponholz et al. [79] found that PCT level is increased 
in patients with cardiovascular events. Erren et al. [80] reported that 
the increased PCT level is linked to the extent of atherosclerosis in CAD 
patients and peripheral arterial disease. In atherosclerotic patients, 
ischemia and inflammatory processes cause PCT production. In 
addition, increased levels of PCT in the setting of CAD are more as a 
result of non-specific liberation of cytokine in the context of local tissue 
damage to myocardium due to ischemia and necrosis. This explains the 
association between PCT and low-grade inflammatory activity within 
the vascular wall caused by atherosclerosis. Schlitt et al. [81] found 
that PCT mRNA expression by peripheral blood mononuclear cells is 
Fig. 4: Correlation between different metabolic parameters and serum C-reactive protein level in cardio-diabetic group
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stimulated indirectly through proinflammatory cytokines (IL-1β, IL-2, 
IL-6, and TNF-α) which play an important role in the atherosclerotic 
process. These together explain the increased PCT concentration in 
diabetic patients with cardiovascular complication. Furthermore, 
patients with severe damage of myocardium after MI had elevated PCT 
level [82]. Remskar et al. [82] observed a relation between PCT level 
and heart failure as well as cardiogenic shock after AMI particularly in 
patients with PCT concentration >0.5 ng/ml.
Microalbumin level is significantly elevated in cardio-diabetic patients 
versus healthy individuals. This finding echoes those of pervious study 
of Klaus et al. [84] who demonstrated that patients who developed CHD 
during follow-up have higher urinary albumin excretion than controls. 
Furthermore, Jensen et al. [85] found a positive correlation between 
urinary albumin excretion rate and AMI. Several hypotheses explain the 
link between microalbuminuria and CVD. One of them suggests that a 
dysfunction of the vascular endothelium causes both microalbuminuria 
and CVD [86,87]. Endothelial impairment can be identified by any change 
in endothelial characteristics that is inappropriate with regard to the 
maintenance of organ function. Therefore, many kinds of endothelial 
impairment could be existed depending on which function is affected 
(e.g., the regulation of hemostasis and fibrinolysis, vasomotor activity, 
permeability to macromolecules, leukocyte adhesion, and vascular 
SMC proliferation). Generalized endothelial impairment is considered 
as a transducer of atherogenic risk factors and is thought to play an 
essential role in both development and progression of atherosclerosis. 
Therefore, the association of microalbuminuria with generalized 
endothelial impairment could explain why microalbuminuria strongly 
predicts CVD. Indeed, microalbuminuria in type 1 and type 2 diabetes is 
usually paralleled by endothelial impairment regarding the regulation 
of hemostasis, fibrinolysis, leukocyte adhesion, and no synthesis and/or 
availability [86]. Jager et al. [88] and Stehouwer et al. [89] mentioned 
that chronic, low-grade inflammation is related to the occurrence and 
progression of microalbuminuria and with risk for atherothrombotic 
disease. From the above considerations, endothelial impairment and 
chronic low-grade inflammation are essential candidates to explain the 
association between microalbuminuria and CVD.
In view of our data, significant positive correlation between serum PCT 
and cholesterol, TG, CRP, LDL, HbA1c, and FBG in diabetic patients has 
been found. Likewise, significant positive correlation has been detected 
between PCT and cholesterol, TG, CRP, and FBG in cardio-diabetic 
patients. These findings are in concert with the reports of Schiopu 
et al. [56] who found that PCT is associated with many of the already 
established cardiovascular risk factors (CRP, hypertension, diabetes, 
and renal function). Furthermore, Sponholz  et al. [79] stated that PCT 
level is associated with CRP and TG concentrations in patient with CAD.
A significant positive correlation between serum CRP level and 
cholesterol, TG, FBG, HbA1c, and LDL in diabetic patients, and also 
between CRP and cholesterol, TG, FBG, and microalbumin in cardio-
diabetic patients has been demonstrated. These results converge with 
the previous report of Seo et al. [90] which showed that levels of hs-CRP 
are significantly correlated with the level of glycosylated hemoglobin, 
LDL/HDL ratio, LDL/total cholesterol (TC) ratio, and TC/TG ratio in 
diabetic patients or patients with CVD. Furthermore, Bahceci et al. [91] 
observed positive correlation between serum hs-CRP and glycated 
hemoglobin in T2DM with or without CHD. Safiullah et al. [92] found 
that fasting plasma glucose, TC, LDL-cholesterol, and HbA1c are higher 
in diabetic patients with abnormal hs-CRP than the diabetic patients 
with normal hs-CRP.
ROC curve was done to detect the best cut-off value of serum PCT 
in diabetic and cardio-diabetic patients. It has proved that PCT at 
concentration 750 ng/l has 87.5% sensitivity and 72.5% specificity. 
Sponholz et al. [79] and Farzad et al. [93] revealed that  procalcitonin 
level is high in patients with cardiovascular disease. In addition, the 
studies of Sponholz et al. [79] and Erren et al. [80] reported that the 
elevated PCT level is related to the extent of atherosclerosis in patients 
with CAD and peripheral arterial disease. In addition, these findings 
indicate that PCT is a biomarker of CAD in type 2 diabetic patients.
The best cut-off value of serum CRP in diabetic and cardio-diabetic 
patients was 42.1 mg/l with 62.5% sensitivity and 82.5% specificity. 
These results are comparable to the findings of Ridker [73] who 
mentioned that increased level of CRP is related to 8-fold increase in 
cardiovascular mortality. Furthermore, Bahceci et al. [91] found that 
hs-CRP levels are increased in patients with CHD, whether they are 
diabetic or non-diabetic than in controls, and the levels of hs-CRP in 
diabetic patient with CHD are also higher than patients with CHD only. 
These observations suggest that CRP is a biomarker of CAD in type 2 
diabetic patients.
CONCLUSION
The present findings provide a clear evidence favoring the clinical value 
of measuring serum level of PCT and CRP as diagnostic candidates for 
cardiovascular complication in patients with T2DM.
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